Small molecule · Inhibitor of menin (MEN1) · developed by Syndax
Revumenib is an orally bioavailable menin inhibitor that blocks the interaction between menin and KMT2A proteins.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 4, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07211958 | Phase 3 | Acute Myeloid Leukemias | Recruiting | SNDX |
| NCT03013998 | Phase 2/3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Recruiting | SNDX |
| NCT05360160 | Phase 1/2 | Acute Myeloid Leukemia | Recruiting | SNDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia
Updated Oct 3, 2026. Something wrong or missing? Report it on the SNDX page.
See SNDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNDX catalysts and pipeline →